Cholera toxin B subunit acts as a potent systemic adjuvant for HIV-1 DNA vaccination intramuscularly in mice

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 5, 2014, Pages 1274-1283

  Hou, Jue ^a,b   Liu, Ying ^a   Hsi, Jenny ^a   Wang, Hongzhi ^b   Tao, Ran ^c   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b HEFEI INSTITUTES OF PHYSICAL SCIENCE   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Cholera toxin B subunit; DNA vaccine; DNA vaccine adjuvant; Immunogenicity; In vitro profiling

Indexed keywords

CHOLERA TOXIN B SUBUNIT; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA; CHOLERA TOXIN; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; GENE EXPRESSION PROFILING; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PROCEDURES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELLS, CULTURED; CHOLERA TOXIN; HIV-1; IMMUNOGENETIC PHENOMENA; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, INBRED C57BL; VACCINATION; VACCINES, DNA;

EID: 84901444936     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28371     Document Type: Article

References (45)

1. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008; 8:235-47; PMID:18194079; http://dx.doi.org/10.1517/14712598.8.2.235
2. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009; 4:e4384; PMID:19197383; http://dx.doi.org/10.1371/journal.pone.0004384
3. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, Gillard P, Jilg W. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284-90; PMID:19856521; http://dx.doi.org/10.1016/j.vaccine.2009.01.040
4. Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849-57; PMID:19835828; http://dx.doi.org/10.1016/j.vaccine. 2009.10.017
5. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010; 2:ra5; PMID:20371470; http://dx.doi.org/10.1126/scitranslmed.3000624
6. Malherbe L, Mark L, Fazilleau N, McHeyzer-Williams LJ, McHeyzer-Williams MG. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 2008; 28:698-709; PMID:18450485; http://dx.doi.org/10.1016/j.immuni.2008.03.014
7. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5; PMID:11130078; http://dx.doi.org/10.1038/35047123
8. Marinaro M, Staats HF, Hiroi T, Jackson RJ, Coste M, Boyaka PN, Okahashi N, Yamamoto M, Kiyono H, Bluethmann H, et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 1995; 155:4621-9; PMID:7594461
9. Lycke N. The mechanism of cholera toxin adjuvanticity. Res Immunol 1997; 148:504-20; PMID:9588829; http://dx.doi.org/10.1016/S0923-2494(98)80144-2
10. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995; 63:1617-23; PMID:7729864
11. Sack DA, Huda S, Neogi PK, Daniel RR, Spira WM. Microtiter ganglioside enzyme-linked immunosorbent assay for vibrio and Escherichia coli heat-labile enterotoxins and antitoxin. J Clin Microbiol 1980; 11:35-40; PMID:6986402
12. George-Chandy A, Eriksson K, Lebens M, Nordström I, Schön E, Holmgren J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect Immun 2001; 69:5716-25; PMID:11500448; http://dx.doi.org/10.1128/IAI.69. 9.5716-5725.2001
13. Isomura I, Yasuda Y, Tsujimura K, Takahashi T, Tochikubo K, Morita A. Recombinant cholera toxin B subunit activates dendritic cells and enhances antitumor immunity. Microbiol Immunol 2005; 49:79-87; PMID:15665457; http://dx.doi.org/10.1111/j.1348-0421.2005.tb03632.x
14. Luci C, Hervouet C, Rousseau D, Holmgren J, Czerkinsky C, Anjuère F. Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin. J Immunol 2006; 176:2749-57; PMID:16493030
15. Eriksson K, Fredriksson M, Nordström I, Holmgren J. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infect Immun 2003; 71:1740-7; PMID:12654787; http://dx.doi.org/10.1128/IAI.71.4.1740-1747.2003
16. Harakuni T, Sugawa H, Komesu A, Tadano M, Arakawa T. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Infect Immun 2005; 73:5654-65; PMID:16113283; http://dx.doi.org/10.1128/IAI.73.9.5654-5665. 2005
17. Sanchez AE, Aquino G, Ostoa-Saloma P, Laclette JP, Rocha-Zavaleta L. Cholera toxin B-subunit gene enhances mucosal immunoglobulin A, Th1-type, and CD8+ cytotoxic responses when coadministered intradermally with a DNA vaccine. Clin Diagn Lab Immunol 2004; 11:711-9; PMID:15242946
18. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8; PMID:1690918; http://dx.doi.org/10.1126/science.1690918
19. Wolff JA, Williams P, Acsadi G, Jiao S, Jani A, Chong W. Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechniques 1991; 11:474-85; PMID:1793583
20. Acsadi G, Jiao SS, Jani A, Duke D, Williams P, Chong W, Wolff JA. Direct gene transfer and expression into rat heart in vivo. New Biol 1991; 3:71-81; PMID:1903987
21. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992; 10:75-88; PMID:1539467; http://dx.doi.org/10.1016/0264-410X(92) 90021-B
22. Sasaki S, Sumino K, Hamajima K, Fukushima J, Ishii N, Kawamoto S, Mohri H, Kensil CR, Okuda K. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J Virol 1998; 72:4931-9; PMID:9573261
23. Hou J, Liu Y, Liu Y, Shao Y. The MSHA strain of Pseudomonas aeruginosa activated TLR pathway and enhanced HIV-1 DNA vaccine immunoreactivity. PLoS One 2012; 7:e47724; PMID:23077664; http://dx.doi.org/10.1371/journal.pone.0047724
24. Braun MC, He J, Wu CY, Kelsall BL. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. J Exp Med 1999; 189:541-52; PMID:9927516; http://dx.doi.org/10.1084/jem.189.3.541
25. Lavelle EC, Grant G, Pusztai A, Pfüller U, O'Hagan DT. Mucosal immunogenicity of plant lectins in mice. Immunology 2000; 99:30-7; PMID:10651938; http://dx.doi.org/10.1046/j.1365-2567.2000.00932.x
26. Pinkhasov J, Alvarez ML, Pathangey LB, Tinder TL, Mason HS, Walmsley AM, Gendler SJ, Mukherjee P. Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model. Cancer Immunol Immunother 2010; 59:1801-11; PMID:20824430; http://dx.doi.org/10.1007/s00262- 010-0906-1
27. Tamura S, Hasegawa H, Kurata T. Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments. Jpn J Infect Dis 2010; 63:8-15; PMID:20093755
28. Price GA, Holmes RK. Evaluation of TcpF-A2-CTB chimera and evidence of additive protective efficacy of immunizing with TcpF and CTB in the suckling mouse model of cholera. PLoS One 2012; 7:e42434; PMID:22879984; http://dx.doi.org/10.1371/journal.pone.0042434
29. Doria-Rose NA, Haigwood NL. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 2003; 31:207-16; PMID:14511953; http://dx.doi.org/10.1016/S1046-2023(03)00135-X
30. Letvin NL. Progress toward an HIV vaccine. Annu Rev Med 2005; 56:213-23; PMID:15660510; http://dx.doi.org/10.1146/annurev.med.54.101601.152349
31. Hamajima K, Sasaki S, Fukushima J, Kaneko T, Xin KQ, Kudoh I, Okuda K. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response. Clin Immunol Immunopathol 1998; 88:205-10; PMID:9714699; http://dx.doi.org/10.1006/clin.1998.4566
32. Okada E, Sasaki S, Ishii N, Aoki I, Yasuda T, Nishioka K, Fukushima J, Miyazaki J, Wahren B, Okuda K. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colonystimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997; 159:3638-47; PMID:9317164
33. Xin KQ, Hamajima K, Sasaki S, Honsho A, Tsuji T, Ishii N, Cao XR, Lu Y, Fukushima J, Shapshak P, et al. Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cellmediated immunity against HIV-1. Immunology 1998; 94:438-44; PMID:9767429; http://dx.doi.org/10.1046/j.1365-2567.1998.00533.x
34. Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT, Tao MH. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160:1320-9; PMID:9570550
35. Sin JI, Kim JJ, Boyer JD, Ciccarelli RB, Higgins TJ, Weiner DB. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 1999; 73:501-9; PMID:9847356
36. Boyer JD, Kim J, Ugen K, Cohen AD, Ahn L, Schumann K, Lacy K, Bagarazzi ML, Javadian A, Ciccarelli RB, et al. HIV-1 DNA vaccines and chemokines. Vaccine 1999; 17(Suppl 2):S53-64; PMID:10506409; http://dx.doi.org/10.1016/S0264- 410X(99)00235-2
37. Lu Y, Xin KQ, Hamajima K, Tsuji T, Aoki I, Yang J, Sasaki S, Fukushima J, Yoshimura T, Toda S, et al. Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin Exp Immunol 1999; 115:335-41; PMID:9933462; http://dx.doi.org/10.1046/j. 1365-2249.1999.00793.x
38. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, Bachmann MF. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 2007; 178:2415-20; PMID:17277148
39. Turner ML, Corcoran LM, Brink R, Hodgkin PD. High-affinity B cell receptor ligation by cognate antigen induces cytokine-independent isotype switching. J Immunol 2010; 184:6592-9; PMID:20483733; http://dx.doi.org/10.4049/ jimmunol.0903437
40. Pinto AR, Reyes-Sandoval A, Ertl HC. Chemokines and TRANCE as genetic adjuvants for a DNA vaccine to rabies virus. Cell Immunol 2003; 224:106-13; PMID:14609576; http://dx.doi.org/10.1016/j.cellimm.2003.08.006
41. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:121-7; PMID:10714678; http://dx.doi.org/10. 1016/S1074-7613(00)80165-X
42. Inaba K, Swiggard WJ, Steinman RM, Romani N, Schuler G, Brinster C. Isolation of dendritic cells. Current protocols in immunology / edited by John E Coligan [et al. 2009; Chapter 3:Unit 3 7.
43. Montgomery CP, Daum RS. Transcription of inflammatory genes in the lung after infection with community-associated methicillin-resistant Staphylococcus aureus: a role for panton-valentine leukocidin? Infect Immun 2009; 77:2159-67; PMID:19237525; http://dx.doi.org/10.1128/IAI.00021-09
44. Sun J, Li D, Hao Y, Zhang Y, Fan W, Fu J, Hu Y, Liu Y, Shao Y. Posttranscriptional regulatory elements enhance antigen expression and DNA vaccine efficacy. DNA Cell Biol 2009; 28:233-40; PMID:19388846; http://dx.doi.org/10.1089/dna.2009.0862
45. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262